Abstract: A method for administering a formulation to an animal involves using a dispenser that includes a top end with one or more openings and a bottom end equipped with a tightening mechanism. The method comprises the steps of contacting the formulation application area with the top end of the dispenser and administering the formulation by adjusting the tightening mechanism. This adjustment pushes the formulation through the openings in the top end, directing it onto the formulation application area. The described method ensures controlled and efficient delivery of the formulation to the intended site on the animal.
Abstract: Various aspects of this disclosure relate to topical anti-inflammatory, analgesic compositions comprising a fatty acid and tryptophan as well as methods of using such compositions. In some specific embodiments, the fatty acid is decanoic acid. Such compositions are generally useful to treat inflammation, and they are specifically useful to treat osteoarthritis.
Abstract: C-7 functionalized artemisinin derivatives, and methods of producing and using C-7 functionalized artemisinin derivatives, for the treatment of malaria. Semi-synthesis of artemisinin analogs based on the functionalization of C-7 through fungal biotransformation. Fungal fermentation techniques were used to add hydroxyl groups to artemisinin positions that are difficult to access chemical, namely C-7.
Type:
Application
Filed:
June 14, 2024
Publication date:
December 26, 2024
Inventors:
Paulo Carvalho, Karine Le Roch, Mitchell Avery, John Williamson, Amar Chittiboyina, Matthew Valdez, Zeinab Chahine, Melinda Baldwin
Abstract: Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.20 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous or non-aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, microemulsion, aerosol spray, non-aerosol spray, serum, solution, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and/or itchiness in the affected area compared to pre-treatment levels.
Type:
Application
Filed:
June 20, 2023
Publication date:
December 26, 2024
Inventors:
Joaquin J. Jimenez, Naiem T. Issa, John P. McCook
Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament, and to processes for the preparation of said compositions.
Type:
Application
Filed:
September 3, 2024
Publication date:
December 26, 2024
Inventors:
Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
Abstract: Described herein are methods for treating hyperoxaluria in a subject with Compound 1, represented by the formula: (Compound 1), a tautomer, a pharmaceutically acceptable salt, a hydrate, a solvate, or a combination thereof. In particular, Compound 1 is Compound 1a or a tautomer thereof in a monosodium and monohydrate form. Also described are methods for treating or preventing kidney stones. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
Abstract: In some embodiments, a method of promoting spinogenesis in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 2 or binding site 3.
Type:
Application
Filed:
April 8, 2024
Publication date:
December 26, 2024
Inventors:
Stella T. Sarraf, Vincent F. SIMMON, Peter W. VANDERKLISH
Abstract: The present disclosure provides methods of improving, enhancing, and/or rejuvernating neuromuscular junction morphology and/or function in a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating subjects afflicted with neurogenic myopathies, aged-induced loss of muscle mass, genetic neuromuscular wasting disorders, or after trauma or injury, among others.
Type:
Application
Filed:
October 19, 2022
Publication date:
December 26, 2024
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Helen M. Blau, Yu Xin Wang, Mohsen Afshar Bakooshli
Abstract: A method for improving cognitive function in a human suffering from a neurodegenerative cognitive disorder includes introducing a therapeutic amount of quaternary ammonium antimuscarinic compound into a body of a human at a first initial time, introducing a therapeutic amount of a cholinesterase inhibitor into the body of the human at a second initial time, releasing the therapeutic amount of the quaternary ammonium antimuscarinic compound into the body of the human at a first rate, and releasing the therapeutic amount of the cholinesterase inhibitor into the body of the human at a second rate. The first rate is different than the second rate.
Abstract: Disclosed is a process for preparing new crystal salt forms of sulfasalazine, in particular a crystal Form A of the D(?)-N-methylglucamine (meglumine) salt of sulfasalazine, a crystal form A of the piperazine salt of sulfasalazine and a crystal Form B of the diethylamine salt of sulfasalazine, and the use thereof in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.
Type:
Application
Filed:
June 27, 2024
Publication date:
December 26, 2024
Inventors:
Marguerite MENSONIDES-HARSEMA, Sebastian BIALLECK
Abstract: The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
Abstract: The present disclosure relates to compounds that modulate (i.e., regulate) proteasome activity, pharmaceutical compositions containing such compounds, and uses of these compounds and compositions for the treatment of muscle wasting. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Application
Filed:
June 12, 2024
Publication date:
December 26, 2024
Inventors:
Maria Gaczynska, Pawel A. Osmulski, Jetze Tepe
Abstract: This document provides methods and materials for treating cancer (e.g., liver cancer such as hepatocellular carcinoma (HCC)) using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors (e.g., a selective SCD1 inhibitor (SSI)) and one or more tyrosine kinase inhibitors.
Type:
Application
Filed:
April 10, 2024
Publication date:
December 26, 2024
Applicant:
Mayo Foundation for Medical Education and Research
Inventors:
John A. Copland, III, Kabir Mody, Justyna J. Gleba, Tushar C. Patel
Abstract: The present disclosure encompasses methods and compositions for extended-release formulations for treating ophthalmic conditions. These formulations comprise a pharmaceutical agent, a cationic polymer, a non-ionic polymer, and a pharmaceutical carrier and are essentially preservative free. The formulations provided herein are particularly useful for sustained and controlled release of drugs and have low side effects.
Type:
Application
Filed:
September 6, 2024
Publication date:
December 26, 2024
Inventors:
Dennis E. Saadeh, Mark L. Baum, Richard L. Lindstrom
Abstract: An application of a receptor-interacting protein 2 (RIP2) inhibitor combined with a chemotherapy drug, particularly, an application of a RIP2 inhibitor combined with a chemotherapy drug in preparation of a drug for treating and/or preventing a tumor. For the first time, the RIP2 inhibitor is found to enhance the antitumor activity of chemotherapy drugs; after combined administration, the ratios of CD45+ cells, neutrophils, dendritic cells, macrophages, CD4+T cells, CD8+T cells, and ?/? T cells in the tumor microenvironment are up-regulated, and tumor chemotherapy resistance is reversed.
Abstract: A bioadhesive nanoparticle (BNP) for long-lasting local drug delivery to treat cancer was developed. The bioadhesive nanoparticles (BNP) are composed of biodegradable polymer such as poly(lactic acid)-hyperbranched polyglycerol (PLA-HPG), encapsulating a chemotherapeutic such as camptothecin (CPT). Nanoparticles (NPs) of PLA-HPG are non-adhesive NPs (NNPs), which are stealthy in their native state, but conversion of the vicinal diols of HPG to aldehydes confers the ability to form strong covalent bonds with amine-rich surfaces. The formulation is administered in combination with immunostimulatory molecules such as CPG and shows unexpectedly better killing of cancer cells.
Type:
Application
Filed:
February 1, 2022
Publication date:
December 26, 2024
Inventors:
Hee-Won Suh, Julia M. Lewis, W. Mark Saltzman, Michael Girardi
Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals. Compounds disclosed herein are cytotoxic or cytostatic (e.g., 7-ethyl camptothecin) prodrugs, conjugated to an integrin binding moiety via cleavable linkers and/or functional spacers.
Type:
Application
Filed:
October 3, 2022
Publication date:
December 26, 2024
Inventors:
Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Mareike WIEDMANN, Anne-Sophie REBSTOCK, Johannes KOEBBERLING, Harvey WONG
Abstract: Disclosed in certain embodiments is an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising: (i) a core comprising a first active agent; (ii) a coating comprising a second active agent layered over the core; and (iii) a material that is sensitive to acidic pH layered over the coated core; wherein the dosage form releases at least about 70% of the second active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.
Type:
Application
Filed:
August 27, 2024
Publication date:
December 26, 2024
Inventors:
Akwete L. Adjei, Sibao Chen, Robert J. Kupper, Vincent Mancinelli
Abstract: The present invention relates to methods for treating patients with chronic cough with nalbuphine compositions as well as treating cough, breathlessness, or dyspnea associated with IPF with nalbuphine compositions, wherein the method provides a therapeutic effect in a patient.
Abstract: A method and composition for mitigating or reducing drug-induced ototoxicity or drug-induced hearing loss in a subject in need of such treatment, comprising: providing a drug delivery system which releases a therapeutic drug upon exposure to reactive oxygen species, wherein the drug delivery system comprises a thermoresponsive hydrogel containing therapeutic drug-loaded crosslinked hybrid nanoparticles and provides sustained therapeutic drug release. The crosslinked hybrid nanoparticles within which the therapeutic drug is loaded may comprise 10,12-Pentacosadiynoic acid (PCDA) and polypropylene sulfide-polyethylene glycol monomethyl ether (PPS-mPEG). The drug-induced ototoxicity or hearing loss may be caused by cisplatin or other platinum-based drugs.
Type:
Application
Filed:
June 21, 2024
Publication date:
December 26, 2024
Applicant:
THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
Abstract: Disclosed in the present invention are a five-membered ring-fused six-membered ring compound, a preparation method therefor, and a pharmaceutical composition and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a pharmaceutically acceptable salt or an isotope compound thereof. The compound of the present invention has an inhibition and/or degradation effect on IRAK4.
Type:
Application
Filed:
April 30, 2024
Publication date:
December 26, 2024
Inventors:
Jason Shaoyun XIANG, Lei WU, Bing ZHANG, Qiang ZHANG, Gang YANG, Rui XU, Shuai YANG, Yue WU, Suyue WANG, Rui YANG
Abstract: The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).
Type:
Application
Filed:
April 15, 2024
Publication date:
December 26, 2024
Inventors:
Yuri RUKAZENKOV, Serban GHIORGHIU, Flavia BORELLINI, Helen MANN
Abstract: This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z?, X?, Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.
Type:
Application
Filed:
October 20, 2022
Publication date:
December 26, 2024
Inventors:
Ji Sook KIM, Jae Yul CHOI, Young Gil AHN
Abstract: The present invention provides methods of treating or preventing new-onset type 1 diabetes with baricitinib, either alone or in combination with insulin, insulin analogues and/or other immunomodulatory agent.
Abstract: Materials and methods useful for therapy, including cancer therapy, that combine an agent that blocks the CD47/SIRP? interaction with a DHFR inhibitor are provided.
Abstract: The present invention relates to combination therapies for treating KRas G12D cancers, In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a. therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use thereof.
Type:
Application
Filed:
October 4, 2022
Publication date:
December 26, 2024
Inventors:
Jill Hallin, James Gail Christensen, Vickie Bowcut, Peter Olson
Abstract: A pharmaceutical composition comprising the compound of Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, is set forth:
Abstract: Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
Type:
Application
Filed:
June 26, 2024
Publication date:
December 26, 2024
Inventors:
Amanda T. WAGNER, James V. CASSELLA, Philip B. GRAHAM, Virginia BRAMAN, Vinita UTTAMSINGH, Jana VON HEHN, Colleen E. HAMILTON
Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
Type:
Application
Filed:
September 5, 2024
Publication date:
December 26, 2024
Inventors:
Lars Daniel Engstrom, Peter Olson, James Gail Christensen
Abstract: Provided is a pharmaceutical composition that can improve tumor immunogenicity. The present disclosure relates to a pharmaceutical composition containing, as an active ingredient, a splicing controlling compound that modulates the activity of serine/arginine-rich splicing factors (SRSFs).
Abstract: The invention relates to pharmaceutical compositions comprising 6-thioguanidine (6-TG) wherein the composition is formulated for release of 6-TG in the distal intestine. Methods for treating a disease or condition of the distal ileum that responds to 6-TG wherein the 6-TG is released in the distal intestine are also disclosed.
Abstract: Disclosed herein are methods of treating a chemosensory dysfunction in a subject, comprising intranasally administering to the subject a phosphodiesterase inhibitor or a salt thereof by a nasal spray device. Also disclosed herein are devices and kits for administering phosphodiesterase inhibitors or salts thereof to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction from a viral infection or another underlying cause of chemosensory dysfunction.
Abstract: The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.
Abstract: The present disclosure provides a method of treating or preventing a liver disorder (e.g., NASH) in a subject with a THR-? agonist, using a biomarker test (e.g., to determine a dose of the THR-? agonist).
Abstract: The present invention relates to an amorphous form of resmetirom. In particular, the present invention relates to an amorphous solid dispersion of resmetirom. The present invention relates to processes for the preparation of amorphous form of resmetirom. The present invention also relates to processes for the preparation of amorphous solid dispersion of resmetirom.
Abstract: The present disclosure provides, for instance, a method of inhibiting resistance to a DDR inhibitor in a subject, the method comprising administering to the subject a GDF15 inhibitor, thereby inhibiting resistance to the DDR inhibitor in the subject. The disclosure also provides combination therapies for cancer, comprising co-administration of a DDR inhibitor and a GDF15 inhibitor.
Abstract: Disclosed are small molecule c-kit inhibitors useful in reducing or eliminating mast cell mediated inflammation. Pharmaceutical formulations containing the c-kit inhibitors are also disclosed. Additionally, methods of treating or preventing a condition, disorder, or disease using the c-kit inhibitors or pharmaceutical formulations thereof are disclosed. The condition, disorder, or disease may be an inflammatory condition, including flares of the inflammatory condition. Exemplary inflammatory conditions relevant to this disclosure include, but are not limited to, mastocytosis, mast cell activation syndrome, hereditary alpha tryptasemia, urticaria, Lyme disease, mast cell leukemia, chronic obstructive pulmonary disease, long COVID, asthma, inflammatory bowel disease, arthritis, allergy, and gout.
Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
Abstract: The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Abstract: The invention is based on the discovery that rho kinase inhibitors, particularly fasudil can be used to treat agitation/anxiety in dementia patients, particularly Alzheimer's disease patients. Fasudil treatment of Alzheimer's patients resulted in improvements in agitation that are orders of magnitude to that observed with other potential therapeutic agents.
Abstract: Provided are a detoxifying agent and detoxifying agent kit for simultaneous detoxification of CO and HCN in the body. The detoxifying agent for removal of carbon monoxide and hydrogen cyanide in the body includes as active ingredients a first inclusion complex wherein a first cyclodextrin dimer represented by general formula (1) below clathrates a first water-soluble metal porphyrin in which the central metal is divalent, and a second inclusion complex wherein a second cyclodextrin dimer represented by general formula (2) below clathrates the first water-soluble metal porphyrin in which the central metal is divalent, and further includes a reducing agent if necessary.
Abstract: The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI] and fecal incontinence [FI] due to weakness in pelvic floor. The treatment comprises of growth and/or repair promoting compound(s) [GRPCs] including but not limited to androgens, androgen receptor modulators, ghrelin, a ghrelin analog, an estrogen, an estrogen receptor modulator, or a combination thereof for delivery into the vagina, anorectal canal or through the mucosa in these viscera to treat pelvic floor disorders.
Abstract: The current methods and compositions provide for a novel therapeutic method for treating patients diagnosed with melanoma, especially those that have become resistant to certain other therapies. Accordingly, certain aspects of the disclosure relate to a method for treating melanoma in a subject, the method comprising administering a composition comprising a ferroptosis-inducing agent to the subject.
Type:
Application
Filed:
June 15, 2022
Publication date:
December 26, 2024
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.
Abstract: The object of the present invention is a pharmaceutical combination of active substances which comprises at least one TLR ligand, at least one compound that labels tumor cells as a target for immune cell attack and at least one anti-CD40 antibody, and further at least one inhibitor of glutamine metabolism. The use of the pharmaceutical combination is for cancer treatment, especially for solid tumor treatments as pancreatic adenocarcinoma.
Type:
Application
Filed:
November 3, 2022
Publication date:
December 26, 2024
Inventors:
Jan ŽENKA, Andrea FREJLACHOVÁ, Radka LENCOVÁ, Ondrej UHER
Abstract: Provided is a method of treating a disease or disorder in a patient. The method comprises administering a psychoactive tryptamine derivative to the patient in a manner sufficient to treat the disease or disorder. In these embodiments, the disease or disorder is a neurodevelopmental disease, a neurodegenerative disease, a neurometabolic disease or anxiety. Also provided is a method of diagnosing or monitoring progression or treatment of a disease or disorder in a patient, where the disease or disorder is a neurodevelopmental disease, a neurodegenerative disease, a neurometabolic disease or anxiety. Additionally provided is a method of developing a treatment of a disease or disorder in a patient, where the disease or disorder is a neurodevelopmental disease, a neurodegenerative disease, a neurometabolic disease or anxiety.
Type:
Application
Filed:
November 8, 2022
Publication date:
December 26, 2024
Inventors:
Marvin S. Hausman, Julia V. Perederiy, Kyle H. Ambert, Viviana Trezza